RxDoctor Payments Data

Peter Winkle

Gastroenterology · Cypress, CANPI 1992923460

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,628 of the $5,203 with a category attached, or 69.7%. 11 manufacturers reported payments, led by Mylan Specialty L.p. at 44.6% of the total. Reporting peaked in 2019 at $2,563 and has fallen 99.2% since, to $19 in 2024.

$5,203in general payments, 2019–2025

Across 51 payments — averaging $102.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$2K
  • Pfizer$1K
  • Novo Nordisk AS$1K
  • AbbVie$286
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$177
  • Shionogi Inc$55
  • plus $77 from 5 others
$117,482,946in research payments, 2019–2025

Across 1,453 payments — averaging $80,855 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$22.1M
  • Bristol Myers Squibb$17.2M
  • E.r. Squibb & Sons, L.L.C.$17M
  • AbbVie$14.2M
  • Amgen$14.1M
  • Janssen Research & Development, LLC$6.9M
  • plus $26M from 29 others

What the payments were for

  • Travel & lodging$3,62870%
  • Food & beverage$1,55530%
  • Gifts$200%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,203 in reported general payments places this provider in the 65th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California →

Other gastroenterology in Cypress

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →